Vedanta biosciences presents new data from phase 1 study of ve202, its rationally-defined consortium for the treatment of inflammatory bowel disease, at the international human microbiome consortium congress 2021 (ihmc)

Cambridge, mass.--(business wire)--vedanta biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from clonal cell banks, today announced additional results from a phase 1 study in healthy volunteers of ve202, the company's 16-strain live biotherapeutic product (lbp) candidate for inflammatory bowel disease (ibd). the new data were presented at the international human microbiome consortium congress 2021
PRTC Ratings Summary
PRTC Quant Ranking